drugset / Trial / NCT02323178
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Phase 1/2
Completed
30 enrolled
Groupe Francophone des Myelodysplasies
GlaxoSmithKline · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
Treatment of patients with chronic myelomonocytic leukemia (CMML) and thrombocytopenia.
Timeline
- Start
- 2014-08-07
- Primary completion
- 2018-12
- Completion
- 2021-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 300 mg | — |